Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

Author:

Jänne Pasi A.1,van den Heuvel Michel M.2,Barlesi Fabrice3,Cobo Manuel4,Mazieres Julien5,Crinò Lucio6,Orlov Sergey7,Blackhall Fiona8,Wolf Juergen9,Garrido Pilar10,Poltoratskiy Artem11,Mariani Gabriella12,Ghiorghiu Dana12,Kilgour Elaine13,Smith Paul12,Kohlmann Alexander12,Carlile David J.12,Lawrence David12,Bowen Karin14,Vansteenkiste Johan15

Affiliation:

1. Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts

2. Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands

3. Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France

4. Department of Medical Oncology, Hospital Universitario Málaga General, Instituto de Investigación Biomédica de Málaga, Malaga, Spain

5. Pulmonology Department, Toulouse University Hospital, Toulouse, France

6. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Meldola, Italy

7. Department of Medicine, Pavlov Medical University, St Petersburg, Russia

8. Manchester University and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

9. Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany

10. Medical Oncology Department, University Hospital Ramon y Cajal, Madrid, Spain

11. Department for Clinical and Preclinical Trials, Petrov Research Institute of Oncology, St Petersburg, Russia

12. AstraZeneca, Cambridge, United Kingdom

13. AstraZeneca, Macclesfield, United Kingdom

14. AstraZeneca, Gaithersburg, Maryland

15. Respiratory Oncology Unit, Department of Respiratory Diseases, University Hospital Katholieke Universiteit Leuven, Leuven, Belgium

Publisher

American Medical Association (AMA)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3